Litcius/Paper detail

Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial

Thomas G Evans, Louise Bussey, Elizabeth Eagling-Vose, Kathryn Rutkowski, Chris Ellis, Chris Argent, Paul Griffin, Joshua Kim, Susan Thackwray, Sepehr Shakib, Julia Doughty, John Gillies, Jian Wu, Julian Druce, Melinda Pryor, Sarah Gilbert

2022The Lancet Infectious Diseases41 citationsDOI

Topics & Concepts

MedicineSeasonal influenzaVirologyInfluenza vaccineVaccinationLive attenuated influenza vaccineImmunologyClinical trialSeroconversionTrivalent influenza vaccineVaccine efficacyInternal medicinePhase (matter)ImmunizationImmunogenicityAntibody responsePediatricsIncidence (geometry)Vaccine trialInfluenza Virus Research StudiesImmune responses and vaccinationsT-cell and B-cell Immunology
Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial | Litcius